Image Protect, Inc. (OTC: IMTL) has recently shared an update on its strategic growth vision and long-term revenue objectives, focusing on its flagship product, the InterceptCS™ Cold Sore Prevention System. This innovative device, classified as a Class II Medical Device by Health Canada, aims to prevent cold sores during the prodrome stage, offering a non-drug, clinically tested solution. The company sees a significant market opportunity, with the U.S. market estimated at $1.2 billion annually and the global market exceeding $3.5 billion.
The company is implementing a multi-channel sales strategy to make InterceptCS™ accessible through direct-to-consumer and third-party platforms, including Amazon, Walmart.com, and eBay. With a long-term goal of reaching up to $100 million in annual revenue within five years, Image Protect is focusing on building a recurring revenue model through device sales and thermal activator purchases. Management estimates that each user could generate approximately $200 in annual revenue, projecting significant growth potential.
To support brand awareness and customer acquisition, Global Wellness Products, a subsidiary of Image Protect, is executing a comprehensive marketing strategy. This includes social media campaigns, paid advertising, search engine marketing, and influencer outreach. The company's CEO, Frank Casella, emphasized the product's potential to address a large, underserved market and the importance of a strong recurring revenue model.
Image Protect's forward-looking statements outline ambitious goals, including market expansion and product development, but caution that these are subject to risks and uncertainties. The company's focus on innovative, science-backed wellness solutions positions it as a potential leader in the personal wellness space, with InterceptCS™ leading the way in cold sore prevention.
